



37th Annual Medical & Scientific Conference

Hyperlipidaemia | National and international perspectives

Wednesday 10 - Friday 12 July 2024 | University of Warwick (Coventry)

Programme


British Dietetic Association - endorsement to be applied for
CPD to be applied for via the Royal Colleges of Physicians

Tuesday 9 July

Time	Session duration		Topic	Venue location
16:00 – 18:30	90	Invited participants only CPD not applicable	HEART UK Board meeting Chaired by: Jules Payne + Pete Green	Radcliffe House - Rad space 12
18:00 - 22:00	240		EXHIBITION BUILD	Oculus foyer

Wednesday 10 July

Time	Session duration		Topic	Speaker	Venue location
07:00 - 09:00			Breakfast (<i>Bluebell House residential guests only</i>)		Rootes Building - 1st floor restaurant
08:30			Registration opens		Oculus foyer
08:00 - 09:30	90	Invited participants only CPD not applicable	HEART UK MS&R Committee meeting Chaired by: Prof Handrean Soran		Oculus room OC 1.01 - 1st floor
09:45 - 10:45	60	Invited participants only CPD not applicable	Lipid Interest group meeting Chaired by: Ms Alison Pottle		Oculus room OC 0.02 - grnd floor
11:00 - 12:20	70	Livestream	SESSION ONE Welcome + International Perspectives		Oculus LT 1.05 - 1st floor
11:00 - 11:10	10	Livestream	Chairman's Welcome Dr Peter Green (Chair, HEART UK)		Oculus LT 1.05 - 1st floor
			Co-chairs: Dr Nigel Capps + Dr Pete Green		
11:10 - 11:40	30	Livestream	Plenary speaker Dyslipidemia and Cardiovascular Disease: A Global Perspective Implementable policies to increase awareness, diagnostic, access and adherence to treatments on a global scale. Dr Jean-Luc Eiselé (Geneva, SWITZERLAND)		

11:40 - 12:10	30	Livestream	<p>Plenary speaker International challenges for cardiovascular prevention around lipids. Results of the INTERASPIRE study in 14 countries across all 6 WHO regions Lipids management worldwide falls well below guideline standards, with enormous heterogeneity in outcomes between countries Prof Kornelia Kotseva (London, UK)</p>		
12:10 - 12:20	10		Group discussion		
12:20 - 13:00	40		Lunch		Oculus foyer
13:00 - 14:00	60	Livestream	<p>SESSION TWO NICE v European Guidelines Organised by: Dev Datta + Jules Payne Chaired by: Dr Jai Cegla</p>		
13:00 - 13:25	25		<p>Plenary speaker NICE v other guidelines Prof Riyaz Patel (Professor of Cardiology, UCL, London, UK)</p>		Oculus LT 1.05 - 1st floor
13:25 - 13:50	25		<p>Plenary speaker LDL-C calculation – What comes next after Friedewald? Describing recent advances in low-density lipoproteins and their diagnostic and therapeutic implications. Dr Alan Remaley (Senior Investigator, National Institutes of Health, National Heart, Lung and Blood Institute, Bethesda, Maryland, USA)</p>		Oculus LT 1.05 - 1st floor
13:50 - 14:00	10		Group discussion		
14:00 - 14:30	30		Refreshments Networking Exhibition		Oculus foyer
14:30 - 15:30	60	Livestream	<p>SESSION THREE Joint session with BIHS</p>		
14:30 - 14:55	25		<p>Co-Chairs: BIHS rep + Dev Datta Optimal treatment in Hypertension Dr Kazem Rahimi (Oxford, UK)</p>		Oculus LT 1.05 - 1st floor
14:55 - 15:20	25		<p>How should I manage hypertension in my clinic Dr Pankaj Gupta (Consultant, Department of Metabolic Medicine and Chemical Pathology, University Hospitals Leicester)</p>		Oculus LT 1.05 - 1st floor
15:20 - 15:30	10		Discussion		
15:30 - 16:00	30		Refreshments Networking Exhibition		Oculus foyer
16:00 - 16:40	40	Livestream	<p>Symposia session 1 <i>Programme under development by the sponsor.</i> Sponsored by Sanofi</p>		Oculus LT 1.05 - 1st floor
16:40 - 16:50	10		Changeover		
16:50 - 17:30	40	Livestream	<p>Symposia session 2 <i>Programme under development by the sponsor.</i> Sponsored by Daiichi-Sankyo</p>		Oculus LT 1.05 - 1st floor
17:30 - 17:40	10		Comfort break		
17:40 - 18:40		Livestream	<p>Organised by: Handrean Soran Programme under development</p>		Oculus LT 1.05 - 1st floor

18:40 - 19:10	30	In person only	FH and allied health professional networking session This is a networking session where FH nurses and allied health care professionals working with familial hypercholesterolaemia can meet and share best practice, information on current projects (national or local) or ask for advice about any issues or barriers they are experiencing in their work. We are a supportive group and welcome all newcomers to the field of FH work. Hosted by: Ms Lisa Gritzmacher <i>CPD is not applicable to this session</i>	Oculus - 0.02 grnd floor
19:10 - 20:00	45	In person only	Spotlight on posters - meet the authors An informal session where the audience can meet all the poster authors to discuss their work. This session is unjudged. <i>See poster listing at end of programme</i>	Oculus - 1st floor landing
19:00 - 21:30	180		Welcome and buffet reception	Oculus foyer
19:30:00			Chairman's welcome Dr Pete Green Premium sponsor welcome	
21:30:00			Presentation of the Rianna Wingett award by Dr Pete Green Evening ends	

Thursday 11 July

Time	Session duration		Topic	Speaker	Venue location
07:00 - 09:00			Breakfast (<i>Bluebell House residential guests only</i>)		Rootes Building - 1st floor restaurant
08:00 - 09:00	60	Invited participants only CPD not applicable	Healthcare committee meeting Chaired by: Ms Michaela Nuttall <i>Invited attendance only - CPD is not applicable</i>		Oculus room OC 1.01 - 1st floor
08:30			Registration opens		Oculus foyer
08:30 - 09:10	50		Refreshments Networking Exhibition		Oculus foyer
09:10 - 09:15	5		Opening remarks Prof Dev Datta		Oculus LT 1.05 - 1st floor
	70	Livestream	SESSION FOUR Women and CVD Organised by: Tina Khan + Lorraine Priestley-Barnham Co-chairs: Dr Tina Khan + Prof Gerald Watts (tbc)		
09:15 - 09:35	20		Plenary speaker Empowering change: The EAS call to action on women, lipids and CVD Prof Jeanine Roeters van Lennepe (HOLLAND)		Oculus LT 1.05 - 1st floor
09:35 - 09:55	20		Plenary speaker Cardiovascular risk management during puberty, conception, pregnancy and beyond Dr Antonio de' Marvao (London, UK)		Oculus LT 1.05 - 1st floor
09:55 - 10:15	20		Plenary speaker Coronary prevention and lipid management during menopause and INOCA Prof Peter Collins (London, UK)		Oculus LT 1.05 - 1st floor
10:15 - 10:25	10		Panel discussion and Q&A		
10:25 - 10:55	30		Refreshments Networking Exhibition		Oculus ground floor
	75	Livestream	SESSION FIVE Paeds Organised by: Tina Khan + Lorraine Priestley-Barnham		Oculus LT 1.05 - 1st floor

			Co-chairs: Ms Lorraine Priestley-Barnham + Dr Uma Ramaswami	
10:55 - 11:15	20		Unlocking the Future; Familial Hypercholesterolaemia and the Newborn Genomes Programme What are the potential benefit and possible drawbacks of identifying families with FH by whole genome sequencing of a newborn baby? Prof Steve Humphries (London, UK)	
11:15 - 11:35	20		Navigating paediatric Homozygous FH management Dr Mike Champion , Consultant Paediatrician & Clinical Lead, Inherited Metabolic Conditions, Evelina, London, UK	
11:35 - 11:55	20		Challenges in Paediatric Homozygous FH Management, Insights from Sheffield A case study based presentation highlighting the challenges faced in managing children with Homozygous Familial Hypercholesterolaemia. Miss Nichola Cowie (Senior Clinical Nurse Specialist in Metabolic Medicine, Sheffield Children's Hospital, Sheffield, UK)	
11:55 - 12:10	15		Panel discussion and Q&A	
12:10 - 12:45	35	Livestream	Paeds sponsored session <i>Programme under development by the sponsor.</i> Sponsored by Ultragenyx	Oculus LT 1.05 - 1st floor
12:45 - 13:35	50		Lunch Networking Exhibition	Oculus ground floor
12:45 - 13:35	50	Invited participants only CPD not applicable	Simon Broome committee meeting Chaired by: Dr Nigel Capps	Oculus room OC 1.01 - 1st floor
13:00 - 13:10	10	In person only	Premium sponsor "Meet the expert" Hosted on the Amgen stand	Amgen stand
13:05 - 13:35	30	In person only	Lunch and Learn What is the changing role of the pharmacist? Organised by: Peter Penson <i>CPD is not applicable to this session</i>	Oculus mtg OC 0.02 - grnd floor
13:35 - 14:45	70	Livestream	SESSION SIX Diet and Lifestyle Organised and Chaired by: Lynne Garton (Dietetic Adviser at HEART UK)	Oculus LT 1.05 - 1st floor
			Session 1: Panel discussion on the dietary management of metabolic lipid conditions Dr Alan Flanagan , University of Surrey, UK Dr Kofi Antwi , Specialist Registrar, University of Bristol, UK Mr Simon Tapley , Specialist Adult Dietitian for Inherited Metabolic Disorders, University of Bristol, UK	
			Session 2: An update on HEART UK's Diet Quizzes to support the dietary management of cholesterol Ms Elphee Medici , Nutrition Consultant, UK	
14:45 - 15:20	35		Refreshments Networking Exhibition	Oculus foyer
	75	Livestream	SESSION SEVEN Abstracts of free communications Medical & Scientific Oculus LT 1.05 - 1st floor	SESSION SEVEN Abstracts of free communications Primary & Healthcare Oculus LT 0.03 - ground floor
			Co-chairs: TBC	Co-chairs: Michaela Nuttall + Pete Green

15:20 - 15:30	10		FC 1	FC 6	
			Genetic Landscape of Familial Chylomicronaemia Syndrome (FCS) and Multifactorial Chylomicronaemia Syndrome (MCS) in United Kingdom	Challenges and opportunities for identifying people with Familial Hypercholesterolaemia in the UK: Evidence from the National FH PASS database	
			Bilal Bashir (University of Manchester, UK)	Edward Cox (University of York, UK)	
15:30 - 15:35	5		Discussion	Discussion	
15:35 - 15:45	10		FC 2	FC 7	
			The long-term, real-world effectiveness and safety of lomitapide in homozygous familial hypercholesterolaemia (HoFH): Nine-year data from the Lomitapide Observational Worldwide Evaluation Registry (LOWER)	Bempedoic acid: real-world efficacy and tolerability in lipid clinics across three UK Centres	
			Jaimini Cegla (Imperial College Healthcare NHS Trust, London, UK)	Agnieszka Jakubowska (East and North Hertfordshire NHS Trust, Stevenage, UK)	
15:45 - 15:50	5		Discussion	Discussion	
15:50 - 16:00	10		FC 3	FC 8	
			Variants in LPA are associated with mutation-negative Familial Hypercholesterolaemia: whole genome sequencing analysis in the 100,000 Genomes Project	Lomitapide in paediatric patients with homozygous familial hypercholesterolaemia (HoFH) – Analysis of patient-level LDL-C reduction, fat soluble vitamins, lipoproteins and patient maturation from the APH-19 study	
			Marta Futema (University College London, UK)	Zsuzsanna Tamas (Chiesi Pharmaceuticals, Bois-Colombes, France)	
16:00 - 16:05	5		Discussion	Discussion	
16:05 - 16:15	10		FC 4	FC 9	
			HMGCoAR autoantibodies: hidden in plain sight?	Hypertriglyceridaemia and Cardiovascular Autonomic Function in Patients Without Diabetes Mellitus	
			Gavin Mercer-Smith (Newcastle upon Tyne Hospitals NHSFT, Newcastle upon Tyne, UK)	Bilal Bashir (University of Manchester, UK)	
16:15 - 16:25	5		Discussion	Discussion	
16:25 - 16:30	10		FC 5	FC 10	
			Efficacy and safety of statins, ezetimibe and statins-ezetimibe therapies for children and adolescents with heterozygous familial hypercholesterolaemia: Systematic review, pairwise and network meta-analyses of randomised controlled trials	Clinical Service Quality and Unmet Needs in Homozygous Familial Hypercholesterolaemia Patients: Insights from UK Tertiary Centres	
			Alexis Llewellyn (University of York, UK)	Bilal Bashir (University of Manchester, UK)	
16:30 - 16:35	5		Discussion	Discussion	
16:35 - 17:05	30		Refreshments Networking Exhibition		Oculus foyer
	60	Livestream	SESSION EIGHT		
			Chair: Prof Handrean Soran		
			Keynote Myant lecture: An International Perspective on Models of Care for FH International experience on gaps in care for FH will be reviewed and clinical and implementation guidance for closing these gaps will be presented based on contemporary evidence.		
17:05 - 18:05	60		Prof Gerald Watts (Perth, AUSTRALIA)		Oculus LT 1.05 - 1st floor
18:05 - 18:10	5		Day two closing remarks		
19:00 - 19:30			Pre dinner drinks reception		Panorama Suite (2nd floor, Rootes Building)
19:30 - 23:30			Conference dinner		Panorama Suite (2nd floor, Rootes Building)

Friday 12 July

Time	Session duration		Topic	Speaker	Venue location
07:00 - 09:00			Breakfast (Bluebell House residential guests only)		Rootes Building - 1st floor restaurant
08:30			Registration opens		Oculus foyer
08:00 - 09:00		Invited participants only CPD not applicable	Apheresis Working Group committee meeting Chaired by: Prof Dev Datta		Oculus room OC 0.02 - grnd floor
08:30 - 09:30	60		Refreshments Networking Exhibition		Oculus foyer
08:50 - 09:50	60	In person only	Spotlight on posters session		Oculus first floor landing
			Moderated only		
			Judges Gerald Watts, Nigel Capps, Andreas Tridimas , Tina Khan (reserve - Lorraine Priestley-Barnham)		
		MP 01	Using cardiovascular and imaging biomarkers to identify patients with familial hypercholesterolaemia Wiaam Al-Hasani (Guy's & St Thomas Hospitals, London, UK)		
		MP 02	A tale of 2 pregnancies: the biochemical trends, medical management, and outcomes of hypertriglyceridemia in pregnancy secondary to multi-factorial chylomicronaemia syndrome (MCS) and extreme ketogenic/carnivorous diet Nathan Cantley (Bristol Royal Infirmary, University Hospitals of Bristol and Weston NHSFT, UK)		
		MP 03	A New Diagnosis of Familial Chylomicronaemia Syndrome in a 15-Year-Old Male: From Lab to Clinic Samir Elgerray (Nottingham University Hospitals NHS Trust, Nottingham, UK)		
		MP 04	Target gene selection and design of precise base editing therapies for atherosclerotic cardiovascular disease Fred Fiedorek (Verve Therapeutics, Boston, USA)		
		MP 05	Free Circulating PCSK9 is Positively Correlated with Body Mass Index in Healthy Volunteers Anoushka Kamath (University of Manchester, UK)		
		MP 06	Ketogenic diet and extreme hypercholesterolaemia: A case of polygenic hypercholesterolemia Tina Mazaheri (Imperial College Healthcare NHSFT, London, UK)		
		MP 07	Real-world efficacy and side effect profile of bempedoic acid in a tertiary centre lipid clinic Kian Parsapour Moghadam (Imperial College London, UK)		
		MP 08	Statin Treatment in Type 1 Diabetes is Not Associated with Diabetic Peripheral Neuropathy Raabya Pasha (University of Manchester, UK)		
		MP 09	Update on the United Kingdom Paediatric FH Register: Working towards new evidence on when children with Familial Hypercholesterolaemia should start lipid lowering therapies Laila Tata (University of Nottingham, UK)		
		MP 10	Ketogenic Diet – a culinary delight but is there a cautionary tale? Rajalakshmi Valaiyapathi (King's College Hospital NHSFT, London, UK)		
09:50 - 10:00	10		Comfort break		
	85		SESSION NINE - sponsored symposia		
10:00 - 10:40	40	Livestream	Symposia session 3 <i>Programme under development by the sponsor.</i> Sponsored by Amarin		Oculus LT 1.05 - 1st floor
10:40 - 10:50	5		Changeover		

10:50 - 11:30	40	Livestream	Symposia session 4 Programme under development by the sponsor. Sponsored by Amgen	Oculus LT 1.05 - 1st floor
11:30 - 11:50	20		Refreshments Networking Exhibition	Oculus foyer
		Livestream	SESSION TEN	
11:50 - 13:10	80		Clinical Lipidology Live Live patient case studies and discussion Facilitator: Prof Dev Datta Panel members: Case study authors in audience	Oculus LT 1.05 - 1st floor
13:10 - 13:20	10	Livestream	Presentation of prizes and awards Closing remarks Dr Pete Green (Chair - HEART UK)	
			Unmoderated posters	
			Networking session Wed 10 July 19:10-20:00 hrs	
			P11 Assessing the real-world efficacy of inclisiran: Findings from a single-centre study Rehan Aftab (Imperial College London, UK)	
			P12 Transforming lipid pathway in primary care through system partnership and virtual lipid multidisciplinary team approach Pei-Theng Aizlewood (West Yorkshire Integrated Care Board, Yorkshire, UK)	
			P13 A Systematic Approach to Lipid-Lowering Treatment Intensification in a Primary Care Population with Cardiovascular Disease Nicholas Ashley (Royal United Hospital, Bath, UK)	
			P14 Supporting Primary Care with Lipid Optimisation - The impact of a virtual integrated lipid optimisation service Alia Awni (Leeds Teaching Hospitals NHS Trust, Leeds, UK)	
			P15 A South London cardiovascular disease (CVD) prevention fellowship to reduce CVD risk and upskill primary care clinicians Nathan Beencke (Heath Innovation Network, London, UK)	
			P16 Integrated lipidology service for secondary prevention (2-year funded project) Mo Bullen (Lincolnshire Community Health Services#, Lincoln, UK)	
			P17 Lipid Optimisation for Acute Stroke and TIA patients: Benchmarking Against the AHSN Pathway Alexandra Cann (Imperial College Healthcare NHSFT, London, UK)	
			P18 "Direct to Test" – Optimising Lipid Clinic Resources for Primary Care Referrals for Familial Hypercholesterolaemia Genetic Testing Peter Carey (South Tyneside and Sunderland NHSFT, Sunderland, UK)	
			P19 The use of Inclisiran in a patient undergoing lipoprotein apheresis and an observed lowering effect on Lp(a) Claire Chalwin (Royal Brompton & Harefield Hospitals, London, UK)	
			P20 Improving cardiovascular disease outcomes of CORE2oPLUS patient population using an integrated outreach multidisciplinary team community hub model James Chapman (South East Leeds GP Federation Group, Leeds, UK)	
			P21 The characterisation of LDL-C target achievement in patients attending diabetic foot clinic Qaisar Farooq (Heartlands Hospital, Birmingham, UK)	
			P22 Systematic Opportunistic Lipid Optimisation (SOLO) – an initiative to opportunistically improve secondary prevention for medical inpatients Jonathan Fenwick (Gateshead Health NHSFT, Gateshead, UK)	
			P23 Atherosclerotic cardiovascular disease residual risk reduction – an innovative cardio-renal-metabolic multidisciplinary team approach to secondary prevention	

	Jonathan Fenwick (Gateshead Health NHSFT, Gateshead, UK)	
P24	West Midlands Familial Hypercholesterolaemia Service - Cascading an innovative model of delivery	
	Elaine George (Queen Elizabeth Hospital, Birmingham, UK)	
P25	Out-of-surgery screening programme with innovative smartphone-enabled digital CVD risk assessment tool holds promise to improve CVD outcomes	
	Vladimir Gubala (Vital Signs Solutions, Cambridge, UK)	
P26	Barts Health Quality Improvement Project: Familial Hypercholesterolaemia Genetic Testing – Can Commercial Providers Support Clinical Services to Meet Targets?	
	Cararina Guerreiro (St Bartholomew's Hospital, London, UK)	
P27	Addressing Cardiovascular Health Inequity: A Multidisciplinary Programme for Optimising Lipid Management in North East London	
	Nadya Hamed (Barts Health NHS Trust, London, UK)	
P28	Identifying enablers for Pharmacists to demonstrate their competence to provide high-quality, consistent Familial Hypercholesterolaemia gene testing	
	Nadya Hamed (Barts Health NHS Trust, London, UK)	
P29	An audit of the impact of clinical biochemists in the lipid clinic	
	Shonagh Haslam (Lancashire Teaching Hospitals NHS Trust, Preston, UK)	
P30	Introduction of a Lipid MDT to improve outcomes for individuals attending Cardiac Rehabilitation in Aneurin Bevan University Health Board	
	Sarah Howard (Cardiac Rehabilitation Aneurin Bevan University Health Board (ABUHB), Abergavenny, UK)	
P31	Implementing Novel Therapies and Pathways at scale across a Primary Care Network using Clinical Pharmacists	
	Mamoud Khodadi (Affinity Care PCN, Bradford, UK)	
P32	Case study: liver transplantation for a case of homozygous familial hypercholesterolemia with subsequent evolocumab therapy	
	Lakshmi Lakkineni (Imperial College London, UK)	
P33	Assessing polygenic hypercholesterolaemia and raised lipoprotein(a) in a diverse multi-ethnic cohort	
	Rajalakshmi Valaiyapathi (King's College Hospital NHSFT, London, UK)	
P34	Eicosapentaenoic acid (EPA) inhibits lipoprotein(a) [Lp(a)] with higher rates of oxidation compared to non-modified low-density lipoprotein (LDL) in vitro	
	Preston Mason (Brigham & Women's Hospital< Boston, USA)	
P35	Laboratory lipid service provision across Scotland. A combined survey through the Scotland Clinical Biochemistry Network (SCBN) Lipid subgroup and Association for Laboratory Medicine Scotland Audit Group	
	Karen Mitchell (Aberdeen Royal Infirmary, UK)	
P36	"We did it! I am the first person in my family to reach retirement age". 21 Years of Lipoprotein Apheresis – A Case Study	
	Samantha Mower (Royal Brompton & Harefield Hospitals, London, UK)	
P37	Exploring clinical and genetic variability in familial chylomicronaemia syndrome: A case series study	
	Madhavi Nallagonda (Imperial College Healthcare NHSFT, London, UK)	
P38	Cascade Screening in Familial Hypercholesterolaemia: A simple solution, or is it?	
	James Nurse (University of Southampton, UK)	
P39	PCSK9 inhibitors and achievement of lipid targets: An audit-based evaluation	
	Amal Owaydah (University Hospital of North Durham, UK)	
P40	The effect of exercise training on blood lipids: A systematic review and meta-regression analysis.	
	Neil Smart (University of New England, Armidale, Australia)	

P41	Comparison of package insert vs. real world safety data from branded icosapent ethyl users: a select analysis utilizing MarketScan data	
	Handrean Soran (University of Manchester, UK)	
P42	Audit on heterozygous Familial Hypercholesterolemia within Leeds Teaching Hospitals Trust (LTHT)	
	Ekaahh Sumithran (University of Leeds, UK)	
P43	Cross-sector, multi-disciplinary collaboration for lipid optimisation – a promising model of care in Staffordshire and Stoke-on-Trent	
	Helen Wrightson (University Hospitals of North Midlands, Stoke-on-Trent, UK)	